Catalog No.
DHD30801
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
CD138, SDC1, SDC, Syndecan-1, SYND1
Concentration
0.87 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P18827
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Indatuximab
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma, PMID: 30930134
Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models, PMID: 29666962
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies, PMID: 28077160
Monoclonal antibodies in myeloma, PMID: 26452191
Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates, PMID: 26927803
Novel agents in the treatment of multiple myeloma: a review about the future, PMID: 27363832
Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development, PMID: 31544840
Emerging antibody-drug conjugates for treating lymphoid malignancies, PMID: 28792782
Emerging immune targets for the treatment of multiple myeloma, PMID: 29421983
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo, PMID: 33149123
Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies, PMID: 33324546
Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate, PMID: 29672587
Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence, PMID: 33195694
Antibody based immunotherapy for multiple myeloma: it's about time, PMID: 26373636
Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues, PMID: 31976021
Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses, PMID: 32153224
Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies, PMID: 24708159
A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer, PMID: 31545001
Syndecan‑1 expression is an independent favourable prognostic marker in oesophageal adenocarcinoma and represents a potential therapeutic target., PMID:37545626
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study., PMID:34529955
Syndecans in cancer: A review of function, expression, prognostic value, and therapeutic significance., PMID:33485180
Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies., PMID:33324546
Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence., PMID:33195694
VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo., PMID:33149123
Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses., PMID:32153224
Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues., PMID:31976021
A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer., PMID:31545001
Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development., PMID:31544840
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma., PMID:30930134
Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate., PMID:29672587
Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models., PMID:29666962
Emerging immune targets for the treatment of multiple myeloma., PMID:29421983
Emerging antibody-drug conjugates for treating lymphoid malignancies., PMID:28792782
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies., PMID:28077160
Novel agents in the treatment of multiple myeloma: a review about the future., PMID:27363832
Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates., PMID:26927803
Monoclonal antibodies in myeloma., PMID:26452191
Antibody based immunotherapy for multiple myeloma: it's about time., PMID:26373636
Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies., PMID:24708159
For research use only. Not for human or drug use.
